Obseva (OBSV) to Release Quarterly Earnings on Thursday

Obseva (NASDAQ:OBSV) is scheduled to announce its earnings results before the market opens on Thursday, November 8th. Analysts expect the company to announce earnings of ($0.46) per share for the quarter.

Obseva (NASDAQ:OBSV) last announced its quarterly earnings data on Wednesday, August 8th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.05. On average, analysts expect Obseva to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of OBSV stock opened at $15.71 on Thursday. The company has a market capitalization of $547.27 million, a P/E ratio of -6.98 and a beta of 1.55. Obseva has a fifty-two week low of $9.05 and a fifty-two week high of $20.35.

A number of research analysts recently weighed in on OBSV shares. Wedbush set a $34.00 price objective on shares of Obseva and gave the company a “buy” rating in a report on Wednesday, October 3rd. HC Wainwright set a $44.00 price objective on shares of Obseva and gave the company a “buy” rating in a report on Wednesday, August 29th. Zacks Investment Research upgraded shares of Obseva from a “sell” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Wednesday, August 1st. TheStreet upgraded shares of Obseva from a “d+” rating to a “c-” rating in a research note on Thursday, October 11th. Finally, Credit Suisse Group started coverage on shares of Obseva in a research note on Thursday, July 19th. They issued an “outperform” rating and a $24.00 price target for the company. Nine research analysts have rated the stock with a buy rating, Obseva has a consensus rating of “Buy” and an average price target of $28.50.

About Obseva

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Read More: Price to Earnings Ratio (PE) Basics

Earnings History for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply